Bristol-Myers Squibb Co (BMY) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $0.69 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.66. The company posted revenue of $4881.00 million in the period, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016.
Bristol-Myers Squibb Co closed down -1.81 points or -2.37% at $74.66 with 74,12,412 shares getting traded on Thursday. Post opening the session at $75.41, the shares hit an intraday low of $74.5 and an intraday high of $76.48 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Jul 11, 2016, Lamberto Andreotti (director) sold 23,200 shares at $74.65 per share price. According to the SEC, on Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at $72.69 per share price. On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.